Tech Company Financing Transactions
ImmusanT Funding Round
ImmusanT closed a funding round on 9/12/2018. Investors included JDRF T1D Fund.
Transaction Overview
Company Name
Announced On
9/12/2018
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
JDRF T1D Fund (Jonathan Behr)
Proceeds Purpose
With the funds, ImmusanT plans to accelerate the translation of insights and clinical experience gained from its celiac disease program to the development of a novel vaccine candidate for T1D.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 700
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
ImmusanT is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Leslie Williams
Chief Medical Officer
Kenneth Truitt
Chief Scientific Officer
Robert Anderson
Vice President
Joyce Pinkham
VP - Bus. Development
Matan Dabora
VP - Finance
Jonathan Yeadon
VP - Operations
Kristin Neff
Browse more venture capital transactions:
Prev: 9/12/2018: TrueVault venture capital transaction
Next: 9/12/2018: InfoBionic venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs